Wednesday, July 8, 2026

pharma · Solid Tumor, Adult · Solid Tumor · CTMX

CytomX Therapeutics

CytomX Therapeutics is a pharma organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CTMX. Primary therapeutic focus areas include Solid Tumor, Adult, Solid Tumor, Neoplasms, Solid Tumor

South San Francisco, USA HQ
98 Employees
Public company Type
CTMX · NYSE Ticker
Company details
Status
Public
HQ
South San Francisco, USA
Employees
98
Programs
8
Drugs
0
Patents
62
Clinical program

CX-188

Phase 1 · small molecule · Solid Tumor, Adult

CX-188 for Solid Tumor, Adult is a Phase 1 program (small_molecule) at CytomX Therapeutics with 1 ClinicalTrials.gov record(s).

← All CytomX Therapeutics projects Phase 1 small molecule terminated

Internal code CTMX-M-188-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
CytomX Therapeutics
Phase
Phase 1
Modality
small_molecule
Indication
Solid Tumor, Adult
Status
terminated
Trials
1

Clinical trials